Kiniksa Pharmaceuticals (KNSA) Investor Presentation - Slideshow

14K multiple recurrence target patient population Time 2021 2022 2023 Based on first and only FDA-approved therapy for recurrent pericarditis, in-line with specialty biologics with Breakthrough Therapy and Orphan Drug designation • Payer engagement has increased awareness of recurrent pericarditis and the differentiated value of ARCALYST • The distribution network for ARCALYST was developed to provide a high and consistent level of patient support with broad access. Network pharmacies provide customized ser ...